TSX · BLCO.TO
Bausch + Lomb Corporation
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
Loading market information…
TSXV · GSD.V · CAD
Stock price
Quote as of Oct 29, 2026, 03:10 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
Devonian Health Group, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Devonian Health Group, Inc. is a clinical-stage pharmaceutical company. The firm is engaged in the development of drugs for a range of autoimmune and fibroinflammatory conditions, using novel therapeutic approaches to address unmet medical needs. It offers therapeutic and cosmeceutical products. Its drug candidate, Thykamine product is issued from Devonian’s SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The company was founded by Andre P. Boulet on March 27, 2015 and is headquartered in Montmagny, Canada.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:26 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
CA$28.75+CA$0.19 (+0.67%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.3% below the high.
CA$33.67+CA$0.85 (+2.59%)
Apotex Health Corp.’s quoted price sits in the upper half of its reported 52-week range, 16.2% below the high.
$13.08-$0.56 (-4.11%)
AbCellera Biologics Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.92% below the high.
$37.54+$1.20 (+3.3%)
Xenon Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.33% below the high.
CA$12.41+CA$2.74 (+28.34%)
Bausch Health Companies Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.9% below the high.
$17.21-$0.15 (-0.86%)
Aurinia Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 10.6% below the high.
CA$26.76+CA$0.46 (+1.75%)
Extendicare Inc.’s quoted price sits in the lower half of its reported 52-week range, 31.63% below the high.
CA$19.92+CA$0.06 (+0.3%)
Sienna Senior Living Inc.’s quoted price sits in the lower half of its reported 52-week range, 17.24% below the high.
